News Briefing channel feed

No­var­tis' brain de­liv­ery plat­form op­tion deal worth up to $175M; Neu­mora's next steps

7 hours ago

Re­cur­sion takes full rights to rare ge­net­ic dis­or­der drug; CStone out-li­cens­es can­cer drug in Eu­rope

Yesterday

De­nal­i's Hunter syn­drome ther­a­py gets pri­or­i­ty re­view; LENZ inks Cana­da deal

2 days ago

Cloud­break’s shares stum­ble in Hong Kong de­but; Sino­vac squares off against ac­tivist

6 days ago

Organon stops work on drug once viewed as ‘game-chang­ing’; Next­Point culls an as­set

Last week

Broad In­sti­tute con­ducts lay­offs as it preps for cuts in fed­er­al fund­ing; Dyne’s fi­nanc­ing

Last week

IN­mune Bio’s Alzheimer’s drug fails Phase 2; Bridge­Bio sells some AT­TR-CM roy­al­ties

Last week

BioCryst sells Or­ladeyo busi­ness in Eu­rope; UCB gets a Phase 3 win for Fin­tepla

Last week

Edge­wise de­tails piv­otal plans in Beck­er mus­cu­lar dy­s­tro­phy; Kymera’s $250M of­fer­ing

Last week

Ar­bu­tus re­gains rights to he­pati­tis B as­set in Chi­na; Forte’s $75M of­fer­ing

2 weeks ago

Ar­riVent plots next steps for lung can­cer drug; Neu­ron23's $96.5M raise

3 weeks ago

For­ma­tion Bio’s up to €545M li­cens­ing deal with Sanofi; Ot­su­ka, Har­bour Bio­Med team up

3 weeks ago

FDA OKs new la­bel ex­pan­sions for Dupix­ent and In­cyte's Mon­ju­vi

3 weeks ago

Bavar­i­an Nordic's PRV goes for $160M; Bio­mea to ad­vance GLP-1 in­to tri­als

3 weeks ago

Prothena moves for­ward with lay­offs; Aldeyra re­sub­mits dry eye drug to FDA

4 weeks ago

In­cyte’s promis­ing throm­bo­cythemia drug; Cres­cent Bio­phar­ma rais­es $200M in PIPE

4 weeks ago

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

4 weeks ago

ADC Ther­a­peu­tics re­veals lay­offs, $100M PIPE; Third Har­mon­ic seeks buy­er for as­set

4 weeks ago

Lil­ly pledges more than $650M to mus­cle health biotech; Co­gent gets $50M

4 weeks ago

In­smed’s stock ral­lies on PAH da­ta; Uni­cy­cive aims to re­solve CD­MO is­sues

5 weeks ago

Avid­i­ty to seek ac­cel­er­at­ed ap­proval for FSHD drug; Ax­some to run an­oth­er tri­al

5 weeks ago

Kelun's $250M PIPE; Val­ne­va moves chikun­gun­ya vac­cine to Phase 3 for kids

Last month

Cul­li­nan's deal for T cell en­gager from Chi­na; Kardi­gan buys late-stage heart drug

Last month

Vig­il drug fails a Phase 2; Merus aims to raise $300M

Last month
1234 Next page Last page
A service from the Financial Times